Court quashes assessment notice for Unimed Technologies Ltd., citing inconsistent reasons for reopening.

The Court allowed the petition of Unimed Technologies Ltd. and quashed the notice dated 29.3.2011 to reopen the assessment for the year 2004-2005. The Court found that the reasons for reopening Unimed's assessment were undermined by inconsistent reasons for reopening Sun Pharmaceutical Industries Ltd.'s assessment, leading to the invalidation of Unimed's notice. Sun Pharmaceutical Industries Ltd.'s petition was dismissed, and its assessment would proceed based on the evidence, disregarding the observations made.

---

---

Issues Involved:
1. Validity of the notice to reopen the assessment for the assessment year 2004-2005.
2. Inconsistent stands of the Revenue in reopening assessments of Unimed Technologies Ltd. and Sun Pharmaceutical Industries Ltd.
3. The impact of the demerger of Unimed Technologies Ltd. on the reopening of the assessment.

Detailed Analysis:

1. Validity of the Notice to Reopen the Assessment for the Assessment Year 2004-2005:

The petitioner challenged the notice dated 29.3.2011 issued by the respondent Assessing Officer to reopen the assessment for the assessment year 2004-2005. The original return filed by Unimed Technologies Ltd. was accepted without scrutiny under section 143(1) of the Income Tax Act. The Assessing Officer issued the notice based on the belief that Unimed Technologies Ltd. had transferred technology to Sun Pharma Global Inc. (Sun BVI) for US$ 4,00,000, which was later sold to Caraco for US$ 1.17 crores. The Assessing Officer contended that Sun BVI did not have the necessary infrastructure to add significant value to the technology, implying that the technology was indirectly transferred to Caraco to avoid taxation in India.

2. Inconsistent Stands of the Revenue in Reopening Assessments of Unimed Technologies Ltd. and Sun Pharmaceutical Industries Ltd.:

The petitioner argued that the Assessing Officer had also reopened the assessment of Sun Pharmaceutical Industries Ltd. for the same transaction, suggesting that the technology was developed by Sun Pharmaceutical Industries Ltd. and not Unimed Technologies Ltd. This inconsistency was evident in the reasons recorded for reopening the assessments. In the case of Unimed Technologies Ltd., the Assessing Officer claimed that the technology was developed by Unimed and transferred at an understated price. Conversely, in the case of Sun Pharmaceutical Industries Ltd., the Assessing Officer asserted that Sun Pharmaceutical Industries Ltd. developed the technology and used Unimed Technologies Ltd. and Sun BVI as conduits to transfer the technology to Caraco, thereby avoiding taxes.

The Court noted that both notices for reopening could not coexist as the same income could not be taxed twice. The reasons recorded in the case of Sun Pharmaceutical Industries Ltd. substantially undermined the reasons recorded in the case of Unimed Technologies Ltd. The Court observed that if the Revenue contends that Sun Pharmaceutical Industries Ltd. developed the technology, the grounds for reopening the assessment of Unimed Technologies Ltd. must fail.

3. The Impact of the Demerger of Unimed Technologies Ltd. on the Reopening of the Assessment:

The petitioner also contended that Unimed Technologies Ltd. was demerged in 2009, and Milmet Pharma Ltd., which inherited a division of Unimed Technologies Ltd., could not be held responsible for transactions that took place during the financial year 2003-2004. The Court, however, did not delve into this issue as it quashed the notice for reopening the assessment based on the inconsistency in the Revenue's stands.

Conclusion:

The Court allowed the petition of Unimed Technologies Ltd. and quashed the impugned notice dated 29.3.2011. It was held that the reasons recorded for reopening the assessment of Unimed Technologies Ltd. were substantially destroyed by the reasons recorded for reopening the assessment of Sun Pharmaceutical Industries Ltd. Consequently, the notice for reopening the assessment of Unimed Technologies Ltd. was invalidated. The petition filed by Sun Pharmaceutical Industries Ltd. was dismissed, and the assessment would be based on the material brought on record, irrespective of the observations made.

---